AMERICAN JOURNAL OF OPHTHALMOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=545188, encodeId=967f54518804, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：1883年创刊的老牌杂志，在业内口碑很好，国人的文章不太多，重视创新性和疗效的研究。 4月13日投稿，5月底返回一次大修，虽然是大修但是只有一条关于内容的修改，其他十几条都是杂志社对感兴趣的文章格式的要求，后来又有两次小修，值得一提的是第二次小修要求语言润色，8月初被接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b332105435, createdName=187297379_95427429, createdTime=Sun Aug 06 20:39:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847632, encodeId=a2eb84e632e5, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：眼科学的老牌期刊了，审稿人给了大修意见，感觉很有希望，今年争取能中一篇！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=072c5414108, createdName=ms4191257501199150, createdTime=Thu Oct 11 17:14:44 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2216372, encodeId=4a0422163e220, content=under review by editor是什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ba38293485, createdName=ms5000001882297362, createdTime=Tue Jul 23 08:23:17 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=600704, encodeId=060d600e0454, content=求问投稿20天后状态变成Exec. Editor Complete。之前是under peer review。现在是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/26/16fe8e130dd541acc2bb8b175c039991.jpg, createdBy=9a1c2360766, createdName=Trna11, createdTime=Thu May 28 11:19:42 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189965, encodeId=d77a218996522, content=一个月了还没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bff6445766, createdName=ms6000000566720161, createdTime=Wed Feb 28 20:21:57 CST 2024, time=2024-02-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172934, encodeId=f88821e293490, content=我看了一下这个期刊的要求，好像并没有说接受基础研究类的文章，而且近期发的文章我也看了，都是临床方面的文章？？所以基础研究的文章要么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a429092711, createdName=ms3000001298242474, createdTime=Mon Dec 04 21:47:28 CST 2023, time=2023-12-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196355, encodeId=9f22219635566, content=审稿速度:12.0 经验分享：投稿大修修了有3周之后返回去，过了2周又送审给审稿人，目前只有1个审稿人接受了返修的审稿，紧张。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sun Mar 31 17:00:19 CST 2024, time=2024-03-31, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=886116, encodeId=6ba388611612, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：昨天半夜刚中。 一审送外审6周，大修花3周，修回居然不送外审3周，本文首投命中一共用时3个月。投AJO没试Ophthalmology就是因为审稿快，本来下一备选BJO，没用上。可惜今年降了半分，奖励亏了一台Iphone... 3个Reviewer事儿还挺多，不过意见确实很专业。 老板这个账号投6中1，命中率17% 投之前送了AJE润色，感觉有帮助，比AJO自荐的便宜点。 OA貌似要3600刀？还在考虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a9f3009379, createdName=zhangbl155, createdTime=Thu Sep 17 17:24:29 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189944, encodeId=835721899442b, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：眼免疫 经验分享：进行中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03e09116043, createdName=ms5000000215707615, createdTime=Wed Feb 28 18:59:00 CST 2024, time=2024-02-28, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182655, encodeId=16772182655b0, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：POAG 经验分享：投稿后正在等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ed6405593, createdName=ms4000001092991294, createdTime=Fri Jan 19 16:01:00 CST 2024, time=2024-01-19, status=1, ipAttribution=山东省)]

2017-08-06 187297379_95427429

审稿速度:2.0 | 投稿命中率:25.0
经验分享：1883年创刊的老牌杂志，在业内口碑很好，国人的文章不太多，重视创新性和疗效的研究。
4月13日投稿，5月底返回一次大修，虽然是大修但是只有一条关于内容的修改，其他十几条都是杂志社对感兴趣的文章格式的要求，后来又有两次小修，值得一提的是第二次小修要求语言润色，8月初被接收。

238 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=545188, encodeId=967f54518804, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：1883年创刊的老牌杂志，在业内口碑很好，国人的文章不太多，重视创新性和疗效的研究。 4月13日投稿，5月底返回一次大修，虽然是大修但是只有一条关于内容的修改，其他十几条都是杂志社对感兴趣的文章格式的要求，后来又有两次小修，值得一提的是第二次小修要求语言润色，8月初被接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b332105435, createdName=187297379_95427429, createdTime=Sun Aug 06 20:39:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847632, encodeId=a2eb84e632e5, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：眼科学的老牌期刊了，审稿人给了大修意见，感觉很有希望，今年争取能中一篇！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=072c5414108, createdName=ms4191257501199150, createdTime=Thu Oct 11 17:14:44 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2216372, encodeId=4a0422163e220, content=under review by editor是什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ba38293485, createdName=ms5000001882297362, createdTime=Tue Jul 23 08:23:17 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=600704, encodeId=060d600e0454, content=求问投稿20天后状态变成Exec. Editor Complete。之前是under peer review。现在是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/26/16fe8e130dd541acc2bb8b175c039991.jpg, createdBy=9a1c2360766, createdName=Trna11, createdTime=Thu May 28 11:19:42 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189965, encodeId=d77a218996522, content=一个月了还没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bff6445766, createdName=ms6000000566720161, createdTime=Wed Feb 28 20:21:57 CST 2024, time=2024-02-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172934, encodeId=f88821e293490, content=我看了一下这个期刊的要求，好像并没有说接受基础研究类的文章，而且近期发的文章我也看了，都是临床方面的文章？？所以基础研究的文章要么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a429092711, createdName=ms3000001298242474, createdTime=Mon Dec 04 21:47:28 CST 2023, time=2023-12-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196355, encodeId=9f22219635566, content=审稿速度:12.0 经验分享：投稿大修修了有3周之后返回去，过了2周又送审给审稿人，目前只有1个审稿人接受了返修的审稿，紧张。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sun Mar 31 17:00:19 CST 2024, time=2024-03-31, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=886116, encodeId=6ba388611612, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：昨天半夜刚中。 一审送外审6周，大修花3周，修回居然不送外审3周，本文首投命中一共用时3个月。投AJO没试Ophthalmology就是因为审稿快，本来下一备选BJO，没用上。可惜今年降了半分，奖励亏了一台Iphone... 3个Reviewer事儿还挺多，不过意见确实很专业。 老板这个账号投6中1，命中率17% 投之前送了AJE润色，感觉有帮助，比AJO自荐的便宜点。 OA貌似要3600刀？还在考虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a9f3009379, createdName=zhangbl155, createdTime=Thu Sep 17 17:24:29 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189944, encodeId=835721899442b, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：眼免疫 经验分享：进行中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03e09116043, createdName=ms5000000215707615, createdTime=Wed Feb 28 18:59:00 CST 2024, time=2024-02-28, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182655, encodeId=16772182655b0, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：POAG 经验分享：投稿后正在等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ed6405593, createdName=ms4000001092991294, createdTime=Fri Jan 19 16:01:00 CST 2024, time=2024-01-19, status=1, ipAttribution=山东省)]

2018-10-11 ms4191257501199150

审稿速度:1.0 | 投稿命中率:75.0
经验分享：眼科学的老牌期刊了，审稿人给了大修意见，感觉很有希望，今年争取能中一篇！

161 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=545188, encodeId=967f54518804, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：1883年创刊的老牌杂志，在业内口碑很好，国人的文章不太多，重视创新性和疗效的研究。 4月13日投稿，5月底返回一次大修，虽然是大修但是只有一条关于内容的修改，其他十几条都是杂志社对感兴趣的文章格式的要求，后来又有两次小修，值得一提的是第二次小修要求语言润色，8月初被接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b332105435, createdName=187297379_95427429, createdTime=Sun Aug 06 20:39:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847632, encodeId=a2eb84e632e5, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：眼科学的老牌期刊了，审稿人给了大修意见，感觉很有希望，今年争取能中一篇！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=072c5414108, createdName=ms4191257501199150, createdTime=Thu Oct 11 17:14:44 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2216372, encodeId=4a0422163e220, content=under review by editor是什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ba38293485, createdName=ms5000001882297362, createdTime=Tue Jul 23 08:23:17 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=600704, encodeId=060d600e0454, content=求问投稿20天后状态变成Exec. Editor Complete。之前是under peer review。现在是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/26/16fe8e130dd541acc2bb8b175c039991.jpg, createdBy=9a1c2360766, createdName=Trna11, createdTime=Thu May 28 11:19:42 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189965, encodeId=d77a218996522, content=一个月了还没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bff6445766, createdName=ms6000000566720161, createdTime=Wed Feb 28 20:21:57 CST 2024, time=2024-02-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172934, encodeId=f88821e293490, content=我看了一下这个期刊的要求，好像并没有说接受基础研究类的文章，而且近期发的文章我也看了，都是临床方面的文章？？所以基础研究的文章要么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a429092711, createdName=ms3000001298242474, createdTime=Mon Dec 04 21:47:28 CST 2023, time=2023-12-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196355, encodeId=9f22219635566, content=审稿速度:12.0 经验分享：投稿大修修了有3周之后返回去，过了2周又送审给审稿人，目前只有1个审稿人接受了返修的审稿，紧张。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sun Mar 31 17:00:19 CST 2024, time=2024-03-31, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=886116, encodeId=6ba388611612, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：昨天半夜刚中。 一审送外审6周，大修花3周，修回居然不送外审3周，本文首投命中一共用时3个月。投AJO没试Ophthalmology就是因为审稿快，本来下一备选BJO，没用上。可惜今年降了半分，奖励亏了一台Iphone... 3个Reviewer事儿还挺多，不过意见确实很专业。 老板这个账号投6中1，命中率17% 投之前送了AJE润色，感觉有帮助，比AJO自荐的便宜点。 OA貌似要3600刀？还在考虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a9f3009379, createdName=zhangbl155, createdTime=Thu Sep 17 17:24:29 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189944, encodeId=835721899442b, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：眼免疫 经验分享：进行中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03e09116043, createdName=ms5000000215707615, createdTime=Wed Feb 28 18:59:00 CST 2024, time=2024-02-28, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182655, encodeId=16772182655b0, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：POAG 经验分享：投稿后正在等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ed6405593, createdName=ms4000001092991294, createdTime=Fri Jan 19 16:01:00 CST 2024, time=2024-01-19, status=1, ipAttribution=山东省)]

2024-07-23 ms5000001882297362 来自陕西省

under review by editor是什么情况？

60 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=545188, encodeId=967f54518804, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：1883年创刊的老牌杂志，在业内口碑很好，国人的文章不太多，重视创新性和疗效的研究。 4月13日投稿，5月底返回一次大修，虽然是大修但是只有一条关于内容的修改，其他十几条都是杂志社对感兴趣的文章格式的要求，后来又有两次小修，值得一提的是第二次小修要求语言润色，8月初被接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b332105435, createdName=187297379_95427429, createdTime=Sun Aug 06 20:39:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847632, encodeId=a2eb84e632e5, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：眼科学的老牌期刊了，审稿人给了大修意见，感觉很有希望，今年争取能中一篇！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=072c5414108, createdName=ms4191257501199150, createdTime=Thu Oct 11 17:14:44 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2216372, encodeId=4a0422163e220, content=under review by editor是什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ba38293485, createdName=ms5000001882297362, createdTime=Tue Jul 23 08:23:17 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=600704, encodeId=060d600e0454, content=求问投稿20天后状态变成Exec. Editor Complete。之前是under peer review。现在是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/26/16fe8e130dd541acc2bb8b175c039991.jpg, createdBy=9a1c2360766, createdName=Trna11, createdTime=Thu May 28 11:19:42 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189965, encodeId=d77a218996522, content=一个月了还没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bff6445766, createdName=ms6000000566720161, createdTime=Wed Feb 28 20:21:57 CST 2024, time=2024-02-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172934, encodeId=f88821e293490, content=我看了一下这个期刊的要求，好像并没有说接受基础研究类的文章，而且近期发的文章我也看了，都是临床方面的文章？？所以基础研究的文章要么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a429092711, createdName=ms3000001298242474, createdTime=Mon Dec 04 21:47:28 CST 2023, time=2023-12-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196355, encodeId=9f22219635566, content=审稿速度:12.0 经验分享：投稿大修修了有3周之后返回去，过了2周又送审给审稿人，目前只有1个审稿人接受了返修的审稿，紧张。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sun Mar 31 17:00:19 CST 2024, time=2024-03-31, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=886116, encodeId=6ba388611612, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：昨天半夜刚中。 一审送外审6周，大修花3周，修回居然不送外审3周，本文首投命中一共用时3个月。投AJO没试Ophthalmology就是因为审稿快，本来下一备选BJO，没用上。可惜今年降了半分，奖励亏了一台Iphone... 3个Reviewer事儿还挺多，不过意见确实很专业。 老板这个账号投6中1，命中率17% 投之前送了AJE润色，感觉有帮助，比AJO自荐的便宜点。 OA貌似要3600刀？还在考虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a9f3009379, createdName=zhangbl155, createdTime=Thu Sep 17 17:24:29 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189944, encodeId=835721899442b, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：眼免疫 经验分享：进行中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03e09116043, createdName=ms5000000215707615, createdTime=Wed Feb 28 18:59:00 CST 2024, time=2024-02-28, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182655, encodeId=16772182655b0, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：POAG 经验分享：投稿后正在等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ed6405593, createdName=ms4000001092991294, createdTime=Fri Jan 19 16:01:00 CST 2024, time=2024-01-19, status=1, ipAttribution=山东省)]

2020-05-28 Trna11

求问投稿20天后状态变成Exec. Editor Complete。之前是under peer review。现在是什么意思呢

284 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=545188, encodeId=967f54518804, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：1883年创刊的老牌杂志，在业内口碑很好，国人的文章不太多，重视创新性和疗效的研究。 4月13日投稿，5月底返回一次大修，虽然是大修但是只有一条关于内容的修改，其他十几条都是杂志社对感兴趣的文章格式的要求，后来又有两次小修，值得一提的是第二次小修要求语言润色，8月初被接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b332105435, createdName=187297379_95427429, createdTime=Sun Aug 06 20:39:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847632, encodeId=a2eb84e632e5, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：眼科学的老牌期刊了，审稿人给了大修意见，感觉很有希望，今年争取能中一篇！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=072c5414108, createdName=ms4191257501199150, createdTime=Thu Oct 11 17:14:44 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2216372, encodeId=4a0422163e220, content=under review by editor是什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ba38293485, createdName=ms5000001882297362, createdTime=Tue Jul 23 08:23:17 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=600704, encodeId=060d600e0454, content=求问投稿20天后状态变成Exec. Editor Complete。之前是under peer review。现在是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/26/16fe8e130dd541acc2bb8b175c039991.jpg, createdBy=9a1c2360766, createdName=Trna11, createdTime=Thu May 28 11:19:42 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189965, encodeId=d77a218996522, content=一个月了还没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bff6445766, createdName=ms6000000566720161, createdTime=Wed Feb 28 20:21:57 CST 2024, time=2024-02-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172934, encodeId=f88821e293490, content=我看了一下这个期刊的要求，好像并没有说接受基础研究类的文章，而且近期发的文章我也看了，都是临床方面的文章？？所以基础研究的文章要么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a429092711, createdName=ms3000001298242474, createdTime=Mon Dec 04 21:47:28 CST 2023, time=2023-12-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196355, encodeId=9f22219635566, content=审稿速度:12.0 经验分享：投稿大修修了有3周之后返回去，过了2周又送审给审稿人，目前只有1个审稿人接受了返修的审稿，紧张。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sun Mar 31 17:00:19 CST 2024, time=2024-03-31, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=886116, encodeId=6ba388611612, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：昨天半夜刚中。 一审送外审6周，大修花3周，修回居然不送外审3周，本文首投命中一共用时3个月。投AJO没试Ophthalmology就是因为审稿快，本来下一备选BJO，没用上。可惜今年降了半分，奖励亏了一台Iphone... 3个Reviewer事儿还挺多，不过意见确实很专业。 老板这个账号投6中1，命中率17% 投之前送了AJE润色，感觉有帮助，比AJO自荐的便宜点。 OA貌似要3600刀？还在考虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a9f3009379, createdName=zhangbl155, createdTime=Thu Sep 17 17:24:29 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189944, encodeId=835721899442b, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：眼免疫 经验分享：进行中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03e09116043, createdName=ms5000000215707615, createdTime=Wed Feb 28 18:59:00 CST 2024, time=2024-02-28, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182655, encodeId=16772182655b0, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：POAG 经验分享：投稿后正在等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ed6405593, createdName=ms4000001092991294, createdTime=Fri Jan 19 16:01:00 CST 2024, time=2024-01-19, status=1, ipAttribution=山东省)]

2024-02-28 ms6000000566720161 来自广东省

一个月了还没动静

90 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=545188, encodeId=967f54518804, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：1883年创刊的老牌杂志，在业内口碑很好，国人的文章不太多，重视创新性和疗效的研究。 4月13日投稿，5月底返回一次大修，虽然是大修但是只有一条关于内容的修改，其他十几条都是杂志社对感兴趣的文章格式的要求，后来又有两次小修，值得一提的是第二次小修要求语言润色，8月初被接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b332105435, createdName=187297379_95427429, createdTime=Sun Aug 06 20:39:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847632, encodeId=a2eb84e632e5, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：眼科学的老牌期刊了，审稿人给了大修意见，感觉很有希望，今年争取能中一篇！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=072c5414108, createdName=ms4191257501199150, createdTime=Thu Oct 11 17:14:44 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2216372, encodeId=4a0422163e220, content=under review by editor是什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ba38293485, createdName=ms5000001882297362, createdTime=Tue Jul 23 08:23:17 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=600704, encodeId=060d600e0454, content=求问投稿20天后状态变成Exec. Editor Complete。之前是under peer review。现在是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/26/16fe8e130dd541acc2bb8b175c039991.jpg, createdBy=9a1c2360766, createdName=Trna11, createdTime=Thu May 28 11:19:42 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189965, encodeId=d77a218996522, content=一个月了还没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bff6445766, createdName=ms6000000566720161, createdTime=Wed Feb 28 20:21:57 CST 2024, time=2024-02-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172934, encodeId=f88821e293490, content=我看了一下这个期刊的要求，好像并没有说接受基础研究类的文章，而且近期发的文章我也看了，都是临床方面的文章？？所以基础研究的文章要么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a429092711, createdName=ms3000001298242474, createdTime=Mon Dec 04 21:47:28 CST 2023, time=2023-12-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196355, encodeId=9f22219635566, content=审稿速度:12.0 经验分享：投稿大修修了有3周之后返回去，过了2周又送审给审稿人，目前只有1个审稿人接受了返修的审稿，紧张。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sun Mar 31 17:00:19 CST 2024, time=2024-03-31, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=886116, encodeId=6ba388611612, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：昨天半夜刚中。 一审送外审6周，大修花3周，修回居然不送外审3周，本文首投命中一共用时3个月。投AJO没试Ophthalmology就是因为审稿快，本来下一备选BJO，没用上。可惜今年降了半分，奖励亏了一台Iphone... 3个Reviewer事儿还挺多，不过意见确实很专业。 老板这个账号投6中1，命中率17% 投之前送了AJE润色，感觉有帮助，比AJO自荐的便宜点。 OA貌似要3600刀？还在考虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a9f3009379, createdName=zhangbl155, createdTime=Thu Sep 17 17:24:29 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189944, encodeId=835721899442b, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：眼免疫 经验分享：进行中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03e09116043, createdName=ms5000000215707615, createdTime=Wed Feb 28 18:59:00 CST 2024, time=2024-02-28, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182655, encodeId=16772182655b0, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：POAG 经验分享：投稿后正在等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ed6405593, createdName=ms4000001092991294, createdTime=Fri Jan 19 16:01:00 CST 2024, time=2024-01-19, status=1, ipAttribution=山东省)]

2023-12-04 ms3000001298242474 来自广东省

我看了一下这个期刊的要求，好像并没有说接受基础研究类的文章，而且近期发的文章我也看了，都是临床方面的文章？？所以基础研究的文章要么

94 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=545188, encodeId=967f54518804, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：1883年创刊的老牌杂志，在业内口碑很好，国人的文章不太多，重视创新性和疗效的研究。 4月13日投稿，5月底返回一次大修，虽然是大修但是只有一条关于内容的修改，其他十几条都是杂志社对感兴趣的文章格式的要求，后来又有两次小修，值得一提的是第二次小修要求语言润色，8月初被接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b332105435, createdName=187297379_95427429, createdTime=Sun Aug 06 20:39:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847632, encodeId=a2eb84e632e5, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：眼科学的老牌期刊了，审稿人给了大修意见，感觉很有希望，今年争取能中一篇！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=072c5414108, createdName=ms4191257501199150, createdTime=Thu Oct 11 17:14:44 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2216372, encodeId=4a0422163e220, content=under review by editor是什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ba38293485, createdName=ms5000001882297362, createdTime=Tue Jul 23 08:23:17 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=600704, encodeId=060d600e0454, content=求问投稿20天后状态变成Exec. Editor Complete。之前是under peer review。现在是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/26/16fe8e130dd541acc2bb8b175c039991.jpg, createdBy=9a1c2360766, createdName=Trna11, createdTime=Thu May 28 11:19:42 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189965, encodeId=d77a218996522, content=一个月了还没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bff6445766, createdName=ms6000000566720161, createdTime=Wed Feb 28 20:21:57 CST 2024, time=2024-02-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172934, encodeId=f88821e293490, content=我看了一下这个期刊的要求，好像并没有说接受基础研究类的文章，而且近期发的文章我也看了，都是临床方面的文章？？所以基础研究的文章要么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a429092711, createdName=ms3000001298242474, createdTime=Mon Dec 04 21:47:28 CST 2023, time=2023-12-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196355, encodeId=9f22219635566, content=审稿速度:12.0 经验分享：投稿大修修了有3周之后返回去，过了2周又送审给审稿人，目前只有1个审稿人接受了返修的审稿，紧张。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sun Mar 31 17:00:19 CST 2024, time=2024-03-31, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=886116, encodeId=6ba388611612, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：昨天半夜刚中。 一审送外审6周，大修花3周，修回居然不送外审3周，本文首投命中一共用时3个月。投AJO没试Ophthalmology就是因为审稿快，本来下一备选BJO，没用上。可惜今年降了半分，奖励亏了一台Iphone... 3个Reviewer事儿还挺多，不过意见确实很专业。 老板这个账号投6中1，命中率17% 投之前送了AJE润色，感觉有帮助，比AJO自荐的便宜点。 OA貌似要3600刀？还在考虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a9f3009379, createdName=zhangbl155, createdTime=Thu Sep 17 17:24:29 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189944, encodeId=835721899442b, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：眼免疫 经验分享：进行中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03e09116043, createdName=ms5000000215707615, createdTime=Wed Feb 28 18:59:00 CST 2024, time=2024-02-28, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182655, encodeId=16772182655b0, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：POAG 经验分享：投稿后正在等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ed6405593, createdName=ms4000001092991294, createdTime=Fri Jan 19 16:01:00 CST 2024, time=2024-01-19, status=1, ipAttribution=山东省)]

2024-03-31 MedSci_007 来自吉林省

审稿速度:12.0
经验分享：投稿大修修了有3周之后返回去，过了2周又送审给审稿人，目前只有1个审稿人接受了返修的审稿，紧张。

102 0

[GetPortalCommentsPageByObjectIdResponse(id=545188, encodeId=967f54518804, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：1883年创刊的老牌杂志，在业内口碑很好，国人的文章不太多，重视创新性和疗效的研究。 4月13日投稿，5月底返回一次大修，虽然是大修但是只有一条关于内容的修改，其他十几条都是杂志社对感兴趣的文章格式的要求，后来又有两次小修，值得一提的是第二次小修要求语言润色，8月初被接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b332105435, createdName=187297379_95427429, createdTime=Sun Aug 06 20:39:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847632, encodeId=a2eb84e632e5, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：眼科学的老牌期刊了，审稿人给了大修意见，感觉很有希望，今年争取能中一篇！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=072c5414108, createdName=ms4191257501199150, createdTime=Thu Oct 11 17:14:44 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2216372, encodeId=4a0422163e220, content=under review by editor是什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ba38293485, createdName=ms5000001882297362, createdTime=Tue Jul 23 08:23:17 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=600704, encodeId=060d600e0454, content=求问投稿20天后状态变成Exec. Editor Complete。之前是under peer review。现在是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/26/16fe8e130dd541acc2bb8b175c039991.jpg, createdBy=9a1c2360766, createdName=Trna11, createdTime=Thu May 28 11:19:42 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189965, encodeId=d77a218996522, content=一个月了还没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bff6445766, createdName=ms6000000566720161, createdTime=Wed Feb 28 20:21:57 CST 2024, time=2024-02-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172934, encodeId=f88821e293490, content=我看了一下这个期刊的要求，好像并没有说接受基础研究类的文章，而且近期发的文章我也看了，都是临床方面的文章？？所以基础研究的文章要么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a429092711, createdName=ms3000001298242474, createdTime=Mon Dec 04 21:47:28 CST 2023, time=2023-12-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196355, encodeId=9f22219635566, content=审稿速度:12.0 经验分享：投稿大修修了有3周之后返回去，过了2周又送审给审稿人，目前只有1个审稿人接受了返修的审稿，紧张。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sun Mar 31 17:00:19 CST 2024, time=2024-03-31, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=886116, encodeId=6ba388611612, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：昨天半夜刚中。 一审送外审6周，大修花3周，修回居然不送外审3周，本文首投命中一共用时3个月。投AJO没试Ophthalmology就是因为审稿快，本来下一备选BJO，没用上。可惜今年降了半分，奖励亏了一台Iphone... 3个Reviewer事儿还挺多，不过意见确实很专业。 老板这个账号投6中1，命中率17% 投之前送了AJE润色，感觉有帮助，比AJO自荐的便宜点。 OA貌似要3600刀？还在考虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a9f3009379, createdName=zhangbl155, createdTime=Thu Sep 17 17:24:29 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189944, encodeId=835721899442b, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：眼免疫 经验分享：进行中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03e09116043, createdName=ms5000000215707615, createdTime=Wed Feb 28 18:59:00 CST 2024, time=2024-02-28, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182655, encodeId=16772182655b0, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：POAG 经验分享：投稿后正在等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ed6405593, createdName=ms4000001092991294, createdTime=Fri Jan 19 16:01:00 CST 2024, time=2024-01-19, status=1, ipAttribution=山东省)]

2020-09-17 zhangbl155

审稿速度:2.0 | 投稿命中率:25.0
经验分享：昨天半夜刚中。
一审送外审6周，大修花3周，修回居然不送外审3周，本文首投命中一共用时3个月。投AJO没试Ophthalmology就是因为审稿快，本来下一备选BJO，没用上。可惜今年降了半分，奖励亏了一台Iphone...
3个Reviewer事儿还挺多，不过意见确实很专业。
老板这个账号投6中1，命中率17%
投之前送了AJE润色，感觉有帮助，比AJO自荐的便宜点。
OA貌似要3600刀？还在考虑

226 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=545188, encodeId=967f54518804, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：1883年创刊的老牌杂志，在业内口碑很好，国人的文章不太多，重视创新性和疗效的研究。 4月13日投稿，5月底返回一次大修，虽然是大修但是只有一条关于内容的修改，其他十几条都是杂志社对感兴趣的文章格式的要求，后来又有两次小修，值得一提的是第二次小修要求语言润色，8月初被接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b332105435, createdName=187297379_95427429, createdTime=Sun Aug 06 20:39:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847632, encodeId=a2eb84e632e5, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：眼科学的老牌期刊了，审稿人给了大修意见，感觉很有希望，今年争取能中一篇！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=072c5414108, createdName=ms4191257501199150, createdTime=Thu Oct 11 17:14:44 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2216372, encodeId=4a0422163e220, content=under review by editor是什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ba38293485, createdName=ms5000001882297362, createdTime=Tue Jul 23 08:23:17 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=600704, encodeId=060d600e0454, content=求问投稿20天后状态变成Exec. Editor Complete。之前是under peer review。现在是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/26/16fe8e130dd541acc2bb8b175c039991.jpg, createdBy=9a1c2360766, createdName=Trna11, createdTime=Thu May 28 11:19:42 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189965, encodeId=d77a218996522, content=一个月了还没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bff6445766, createdName=ms6000000566720161, createdTime=Wed Feb 28 20:21:57 CST 2024, time=2024-02-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172934, encodeId=f88821e293490, content=我看了一下这个期刊的要求，好像并没有说接受基础研究类的文章，而且近期发的文章我也看了，都是临床方面的文章？？所以基础研究的文章要么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a429092711, createdName=ms3000001298242474, createdTime=Mon Dec 04 21:47:28 CST 2023, time=2023-12-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196355, encodeId=9f22219635566, content=审稿速度:12.0 经验分享：投稿大修修了有3周之后返回去，过了2周又送审给审稿人，目前只有1个审稿人接受了返修的审稿，紧张。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sun Mar 31 17:00:19 CST 2024, time=2024-03-31, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=886116, encodeId=6ba388611612, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：昨天半夜刚中。 一审送外审6周，大修花3周，修回居然不送外审3周，本文首投命中一共用时3个月。投AJO没试Ophthalmology就是因为审稿快，本来下一备选BJO，没用上。可惜今年降了半分，奖励亏了一台Iphone... 3个Reviewer事儿还挺多，不过意见确实很专业。 老板这个账号投6中1，命中率17% 投之前送了AJE润色，感觉有帮助，比AJO自荐的便宜点。 OA貌似要3600刀？还在考虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a9f3009379, createdName=zhangbl155, createdTime=Thu Sep 17 17:24:29 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189944, encodeId=835721899442b, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：眼免疫 经验分享：进行中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03e09116043, createdName=ms5000000215707615, createdTime=Wed Feb 28 18:59:00 CST 2024, time=2024-02-28, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182655, encodeId=16772182655b0, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：POAG 经验分享：投稿后正在等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ed6405593, createdName=ms4000001092991294, createdTime=Fri Jan 19 16:01:00 CST 2024, time=2024-01-19, status=1, ipAttribution=山东省)]

2024-02-28 ms5000000215707615 来自天津

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：眼免疫
经验分享：进行中

78 0

[GetPortalCommentsPageByObjectIdResponse(id=545188, encodeId=967f54518804, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：1883年创刊的老牌杂志，在业内口碑很好，国人的文章不太多，重视创新性和疗效的研究。 4月13日投稿，5月底返回一次大修，虽然是大修但是只有一条关于内容的修改，其他十几条都是杂志社对感兴趣的文章格式的要求，后来又有两次小修，值得一提的是第二次小修要求语言润色，8月初被接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b332105435, createdName=187297379_95427429, createdTime=Sun Aug 06 20:39:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=847632, encodeId=a2eb84e632e5, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：眼科学的老牌期刊了，审稿人给了大修意见，感觉很有希望，今年争取能中一篇！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=072c5414108, createdName=ms4191257501199150, createdTime=Thu Oct 11 17:14:44 CST 2018, time=2018-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2216372, encodeId=4a0422163e220, content=under review by editor是什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ba38293485, createdName=ms5000001882297362, createdTime=Tue Jul 23 08:23:17 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=600704, encodeId=060d600e0454, content=求问投稿20天后状态变成Exec. Editor Complete。之前是under peer review。现在是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/02/26/16fe8e130dd541acc2bb8b175c039991.jpg, createdBy=9a1c2360766, createdName=Trna11, createdTime=Thu May 28 11:19:42 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189965, encodeId=d77a218996522, content=一个月了还没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bff6445766, createdName=ms6000000566720161, createdTime=Wed Feb 28 20:21:57 CST 2024, time=2024-02-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2172934, encodeId=f88821e293490, content=我看了一下这个期刊的要求，好像并没有说接受基础研究类的文章，而且近期发的文章我也看了，都是临床方面的文章？？所以基础研究的文章要么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a429092711, createdName=ms3000001298242474, createdTime=Mon Dec 04 21:47:28 CST 2023, time=2023-12-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196355, encodeId=9f22219635566, content=审稿速度:12.0 经验分享：投稿大修修了有3周之后返回去，过了2周又送审给审稿人，目前只有1个审稿人接受了返修的审稿，紧张。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Sun Mar 31 17:00:19 CST 2024, time=2024-03-31, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=886116, encodeId=6ba388611612, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：昨天半夜刚中。 一审送外审6周，大修花3周，修回居然不送外审3周，本文首投命中一共用时3个月。投AJO没试Ophthalmology就是因为审稿快，本来下一备选BJO，没用上。可惜今年降了半分，奖励亏了一台Iphone... 3个Reviewer事儿还挺多，不过意见确实很专业。 老板这个账号投6中1，命中率17% 投之前送了AJE润色，感觉有帮助，比AJO自荐的便宜点。 OA貌似要3600刀？还在考虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=226, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a9f3009379, createdName=zhangbl155, createdTime=Thu Sep 17 17:24:29 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189944, encodeId=835721899442b, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：眼免疫 经验分享：进行中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03e09116043, createdName=ms5000000215707615, createdTime=Wed Feb 28 18:59:00 CST 2024, time=2024-02-28, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182655, encodeId=16772182655b0, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：POAG 经验分享：投稿后正在等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ed6405593, createdName=ms4000001092991294, createdTime=Fri Jan 19 16:01:00 CST 2024, time=2024-01-19, status=1, ipAttribution=山东省)]

2024-01-19 ms4000001092991294 来自山东省

审稿速度:3.0 | 投稿命中率:5.0
偏重的研究方向：POAG
经验分享：投稿后正在等消息

91 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务